Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma
Drug‐induced pneumonitis is rare, and can result in death. Here, we present a report of a patient with adenocarcinoma harboring EGFR exon 19 deletion mutation treated with osimertinib as first‐line treatment. After six days of treatment, extremely early onset severe pneumonitis was diagnosed. Discon...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-09-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13565 |
| _version_ | 1828812996914184192 |
|---|---|
| author | June Hong Ahn |
| author_facet | June Hong Ahn |
| author_sort | June Hong Ahn |
| collection | DOAJ |
| description | Drug‐induced pneumonitis is rare, and can result in death. Here, we present a report of a patient with adenocarcinoma harboring EGFR exon 19 deletion mutation treated with osimertinib as first‐line treatment. After six days of treatment, extremely early onset severe pneumonitis was diagnosed. Discontinuation of osimertinib as well as administration of corticosteroid, and retreatment with osimertinib were successful. This case report highlights that extremely early onset severe pneumonitis can occur after osimertinib administration, and retreatment of osimertinib may be a useful treatment option after resolution of pneumonitis. |
| first_indexed | 2024-12-12T09:53:47Z |
| format | Article |
| id | doaj.art-48d9432caec24cdd99d13769bd4886b5 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-12T09:53:47Z |
| publishDate | 2020-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-48d9432caec24cdd99d13769bd4886b52022-12-22T00:28:12ZengWileyThoracic Cancer1759-77061759-77142020-09-011192713271610.1111/1759-7714.13565Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinomaJune Hong Ahn0Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases Yeungnam University Medical Center Daegu South KoreaDrug‐induced pneumonitis is rare, and can result in death. Here, we present a report of a patient with adenocarcinoma harboring EGFR exon 19 deletion mutation treated with osimertinib as first‐line treatment. After six days of treatment, extremely early onset severe pneumonitis was diagnosed. Discontinuation of osimertinib as well as administration of corticosteroid, and retreatment with osimertinib were successful. This case report highlights that extremely early onset severe pneumonitis can occur after osimertinib administration, and retreatment of osimertinib may be a useful treatment option after resolution of pneumonitis.https://doi.org/10.1111/1759-7714.13565Lung cancerosimertinibpneumonitisretreatment |
| spellingShingle | June Hong Ahn Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma Thoracic Cancer Lung cancer osimertinib pneumonitis retreatment |
| title | Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma |
| title_full | Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma |
| title_fullStr | Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma |
| title_full_unstemmed | Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma |
| title_short | Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma |
| title_sort | successful osimertinib retreatment after extremely early onset severe pneumonitis in first line treatment of lung adenocarcinoma |
| topic | Lung cancer osimertinib pneumonitis retreatment |
| url | https://doi.org/10.1111/1759-7714.13565 |
| work_keys_str_mv | AT junehongahn successfulosimertinibretreatmentafterextremelyearlyonsetseverepneumonitisinfirstlinetreatmentoflungadenocarcinoma |